Talha Badar
Talha Badar is an expert in Hematology at Mayo Clinic (United States, Jacksonville) (United States). As of October 2026, ScienceLeadR ranks Talha Badar in the top 1% of experts worldwide for Leukemia. Talha Badar has authored 302 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 5 of them ongoing. SLR score: 1,252 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Transplantation
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 302
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Blinatumomab Consolidation in Real World NCT07117136 — burkitt lymphoma, cells, precursor cell lymphoblastic leukemia-lymphoma, lymphoma, leukemia, b-lymphocytes | N/A | Recruiting | 2025 |
| Understanding the Mechanisms of Clonal and Non clonal Cytopenia Following CAR T Therapy for Multiple Myeloma or CD19 Lymphoproliferative Disorder (LPD) NCT06630104 — cells, research design, genes, genetic testing, bone marrow, blood, follow-up studies, chromatin immunoprecipitation sequencing, neoplasms, chromatin immunoprecipitation, chromatin, electronic health records, genetic counseling, signs and symptoms, multiple myeloma, immunoprecipitation, specimen handling, records, therapeutics, lymphoproliferative disorders, counseling, receptors, antigen, t-cell, cytopenia, bone and bones | N/A | Recruiting | 2024 |
| Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy NCT06279572 — cells, bone marrow, blood, induction chemotherapy, leukemia, drug therapy, leukemia, myeloid, acute, electronic health records, immunotherapy, azacitidine, leukemia, myeloid, specimen handling, records, therapeutics, fluid therapy, t-lymphocytes, medical records, chemotherapy, bone and bones | N/A | Recruiting | 2021 |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax Azacitidine Venetoclax 7 3 or 7 3 Quizartinib in Patients With AML NCT05735184 — genes, administration, oral, safety, pharmaceutical preparations, administration, intravenous, hematologic neoplasms, neoplasms, cytarabine, leukemia, drug therapy, leukemia, myeloid, acute, sarcoma, myeloid, sarcoma, azacitidine, leukemia, myeloid, daunorubicin, therapeutics, mutation, cytosine, chemotherapy | Phase 1 | Recruiting | 2023 |
| Daratumumab for Chemotherapy Refractory Minimal Residual Disease in T Cell ALL NCT05289687 — injections, cells, precursor cell lymphoblastic leukemia-lymphoma, precursor t-cell lymphoblastic leukemia-lymphoma, lymphoma, cytarabine, leukemia, drug therapy, precursor cells, t-lymphoid, vincristine, neoplasm, residual, t-lymphocytes, methotrexate, hyaluronoglucosaminidase, chemotherapy | Phase 2 | Recruiting | 2023 |
LeadR Networks
Main global connection map